---
title: "Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Guidelines questions"
description: "Guidelines questions on Paxlovid (nirmatrelvir; ritonavir) in COVID-19, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Paxlovid: which conditions raise the risk of severe COVID-19 (CDC list)? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/paxlovid--covid-19/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Guidelines questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)

Questions that apply to every indication of Paxlovid are on [Paxlovid (nirmatrelvir; ritonavir), all indications](https://www.evicenter.com/medical-information/paxlovid).

## Guidelines

<a id="paxlovid-high-risk-factors"></a>

### Paxlovid: which conditions raise the risk of severe COVID-19 (CDC list)?

> “Age (50+ years)
>
> Age is the strongest risk factor for progressing to severe COVID-19.<sup>2</sup>
>
> Vaccination status
>
> People who are unvaccinated or not up to date on their COVID-19 vaccinations are at an increased risk of severe COVID-19.<sup>2</sup>
>
> Underlying medical conditions that increase the risk of severe COVID-19 include<sup>2</sup>:
> Diabetes
> Heart conditions
> Smoking, current or former
> Obesity
> Disabilities, including learning disabilities
> Certain racial and/or ethnic minority groups are at increased risk of severe outcomes due to inequities in healthcare and socioeconomic factors.<sup>2</sup>
> Underlying medical conditions and factors associated with higher risk for severe COVID-19<sup>2</sup>
>
> Higher risk (conclusive evidence)
>
> Asthma
> Cancer
> Hematologic malignancies
> Cerebrovascular disease
> Chronic kidney disease*
> People receiving dialysis†
> Chronic lung diseases, limited to:
> Bronchiectasis
> COPD (chronic obstructive pulmonary disease)
> Interstitial lung disease
> Pulmonary embolism
> Pulmonary hypertension
> Chronic liver diseases, limited to:
> Cirrhosis
> Nonalcoholic fatty liver disease
> Alcoholic liver disease
> Autoimmune hepatitis
> Cystic fibrosis
> Diabetes mellitus type 1
> Diabetes mellitus type 2*
> Disabilities, including Down syndrome
> Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)
> HIV
> Mental health conditions, limited to:
> Mood disorders, including depression
> Schizophrenia spectrum disorders
> Neurologic conditions limited to dementia and Parkinson's disease
> Obesity (BMI ≥30 kg/m<sup>2</sup> or ≥95th percentile in children)
> Physical inactivity
> Pregnancy and recent pregnancy
> Primary immunodeficiencies
> Smoking, current and former
> Solid organ or blood stem cell transplantation
> Tuberculosis
> Use of corticosteroids or other immunosuppressive medications
>
> Suggestive higher risk<sup>‡</sup>
>
> Epilepsy
> Hemophilia
> Overweight (BMI ≥25 kg/m<sup>2</sup>, but <30 kg/m<sup>2</sup>)
> Sickle cell disease
> Substance use disorders
>
> Mixed evidence (inconclusive: no conclusions can be drawn from the evidence)
>
> Alpha-1 antitrypsin deficiency
> Bronchopulmonary dysplasia
> Hepatitis B and C
> Hypertension*
> Thalassemia”

Source: [PAXLOVID: High Risk Factors, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/high-risk-factor#:~:text=Age%20%2850%2B%20years%29,Thalassemia)

> “*Indicates presence of evidence for pregnant and nonpregnant people.<sup>2</sup>
> †Risk may be further increased for people receiving dialysis.<sup>2</sup>
> <sup>‡</sup>The language expressed on this page is consistent with CDC guidance, with the exception of risk factors regarding pediatric patients, which were removed from this list. PAXLOVID is not approved for use in pediatric patients.<sup>3</sup>”

Source: [PAXLOVID: High Risk Factors, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/high-risk-factor#:~:text=%2AIndicates%20presence%20of%20evidence%20for,approved%20for%20use%20in%20pediatric)

Note: This list is Centers for Disease Control and Prevention guidance as reproduced on the High-Risk Factors page of the Paxlovid HCP site, which cites the CDC page "Underlying conditions and the higher risk for severe COVID-19" as accessed March 6, 2026. The FAQ page of the same site prints the list without Parkinson's disease, epilepsy, and hemophilia. The EPIC-HR trial used its own risk-factor criteria.

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)
- [Indication](https://www.evicenter.com/medical-information/paxlovid--covid-19/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid--covid-19/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/paxlovid--covid-19/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/paxlovid--covid-19/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid--covid-19/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid--covid-19/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid--covid-19/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid--covid-19/access-and-coverage)
